12.12.2022 18:55:43
|
Regeneron Pharma Announces Positive Data From Mid-stage Study Of Linvoseltamab
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) Monday announced positive initial data from a pivotal Phase 2 expansion cohort evaluating investigational linvoseltamab (formerly REGN5458) at the 200 mg dose recommended for further development in patients with heavily pre-treated, relapsed/refractory (R/R) multiple myeloma.
The results were part of a broader presentation of new and updated data from a Phase 1/2 trial and were shared at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, LA.
Linvoseltamab is an investigational bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing.
"The need for innovative medicines is critical for patients with multiple myeloma who inevitably face a downward spiral of relapses, reduced responses to subsequent therapies, and increasingly shorter remissions," said Naresh Bumma, M.D., Hematologist and Assistant Professor in the Division of Hematology at Ohio State University, and a trial investigator. "At the recommended 200 mg dose in a pivotal Phase 2 trial, linvoseltamab demonstrated early, deep and durable responses in patients living with multiple myeloma who had been on at least three prior therapies, including those with higher risk and high disease burden. These clinically meaningful outcomes at 12 weeks reinforce the positive linvoseltamab results seen in the Phase 1 dose escalation portion, and we look forward to seeing data from more patients and longer follow-up."
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Regeneron Pharmaceuticals Inc.mehr Nachrichten
19.12.24 |
Starker Wochentag in New York: NASDAQ 100-Börsianer greifen zum Handelsstart zu (finanzen.at) | |
18.12.24 |
NASDAQ Composite Index-Wert Regeneron Pharmaceuticals-Aktie: So viel Gewinn hätte ein Regeneron Pharmaceuticals-Investment von vor 5 Jahren eingefahren (finanzen.at) | |
17.12.24 |
Schwacher Handel: NASDAQ 100 letztendlich im Minus (finanzen.at) | |
17.12.24 |
Handel in New York: NASDAQ 100 gibt am Nachmittag nach (finanzen.at) | |
17.12.24 |
NASDAQ 100 aktuell: NASDAQ 100 fällt am Dienstagmittag zurück (finanzen.at) | |
12.12.24 |
Börse New York: NASDAQ 100 schwächelt zum Ende des Donnerstagshandels (finanzen.at) | |
12.12.24 |
Schwacher Handel in New York: NASDAQ 100 verliert am Donnerstagnachmittag (finanzen.at) | |
12.12.24 |
Zurückhaltung in New York: NASDAQ 100 fällt am Mittag (finanzen.at) |